Abstract: Objective To understand the frequency and related impact factors of adverse drug response during TB treatment course in people living with TB/HIV co-infection. Methods Adverse drug response of newly discovered TB/HIV patients in 6 counties of 3 provinces was observed.  Results  A total of 332 TB/HIV patients were observed. The overall incidence of adverse response was 81.6%. Of which, 44.2% in gastrointestinal tract, 13.3% in liver, 11.4% of skin allergies, 24.4% of the blood system, 18.7% of nervous system, 3.6% of bones and joints, 4.2%of kidneys, vision, ears and other reaction, 68.1% of adverse response happened within 30 days of anti-TB treatment, 66.8% lasted for more than 15 days, 87.9% of patients died of illness happened in intensive periods of anti-TB treatment. Smear-positive tuberculosis, low-weight, intravenous drug abuse, late initiation of antiviral treatment are impact factors of severe adverse drug response.  Conclusion Patients living with TB/HIV co-infection has higher incidence and longer duration of adverse drug response than pure TB patients. Therefore, adverse response should be monitored, especially in intensive TB treatment period. Patients with smear positive pulmonary tuberculosis, low weight, intravenous drug abuse, late initiation of anti-viral treatment are the focus population; Anti-viral treatment should be initiated early for patients living with TB/HIV co-infection.

Key words: tuberculosis,pulmonary/drug therapy, HIV infections, superinfection, antitubercular agents